Parameter
| Biomarker | CEA | Full name | Carcinoembryonic antigen | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Recurrence monitoring and prognosis prediction | ||
| Disease | Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Serum (immunoassay) | ||
| Pathobiological Mechanisms | As carcinoembryonic antigen, abnormal expression in the process of tumor progression, associated with tumor invasive, transfer potential, can help assess the risk of disease progression | ||||
| Clinical Availability Status | Clinical usefulness (auxiliary monitoring) : the diagnostic value is limited alone, but the combination with CA19-9 and CA125 can improve the prognosis stratification, which is an important supplement for Lewis antigen negative population | ||||
| Notes and Dynamics | 30% to 60% of patients with PDAC higher expression, are more common in patients with late, late is stronger than CA19-9 PDAC progress independent predictors | ||||